Recently, DHC's independently developed Nucleic Acid Molecular Hybridization Instrument has been granted a Class II Medical Device Registration Certificate (Jing Xie Zhu Zhun 20242220298) by the Beijing Municipal Drug Administration. This breakthrough device will perfectly match with the company's already marketed universal sequencing reaction kits, providing medical institutions with a brand-new solution for nucleic acid molecular hybridization analysis.

Innovative technology, integrated service 

The built-in operating software of the Nucleic Acid Molecular Hybridization Instrument, with its clear user interface and modular experimental procedures, achieves one-click experiment operation, significantly simplifying the operational process. Seamless integration with the intelligent reporting platform Clair automates the interpretation of genetic test results, knowledge base matching, and related annotation information search, ultimately generating clinical reports that include medication recommendations automatically. This marks the birth of a new model of integrated service encompassing detection reagents, testing equipment, and knowledge base platform software.

Compact design, high efficiency 

With its compact size and portability, the device effectively saves laboratory space while conducting nucleic acid molecular hybridization analysis through the principle of fluorescence in situ hybridization without requiring special laboratory conditions, significantly reducing laboratory construction costs. In terms of performance, the module temperature control accuracy is less than 0.5℃， with superior temperature uniformity, ensuring the accuracy and repeatability of experiments. Furthermore, the design of four fluorescence channels and the high repeatability and precision of fluorescence intensity detection further ensure the reliability of the test results.

Rapid detection, huge market potential 

The Nucleic Acid Molecular Hybridization Instrument boasts high detection efficiency, completing sample testing and report generation within 1 hour and 10 minutes, significantly shortening the testing cycle and improving the work efficiency of medical institutions. DHC's PGx gene testing series products have achieved remarkable success in the fields of cardiovascular and cerebrovascular drug gene testing, mental health, immunology, as well as risk prediction gene testing for venous thrombosis, Alzheimer's disease, etc., with an annual sales volume exceeding 600,000 loci and customers across more than a dozen provinces and cities domestically. 

The approval of the Nucleic Acid Molecular Hybridization Instrument registration certificate not only injects new vitality into the PGx gene testing market but also realizes a one-stop functional model from sample testing to automatic report generation. This significantly shortens the testing cycle, significantly reduces costs, and improves the quality of clinical services. This innovative achievement signifies that DHC is taking another step forward in the field of in vitro diagnostics, further broadening its business scope. 

Biotechnology is one of the core business directions of DHC. Since its establishment, the company has always adhered to molecular diagnostics, tumor gene methylation, and other technological platforms as the leading direction, focusing on technological innovation and application innovation, creating a unique R&D platform and product system. The Pharmacogenomics (PGx) gene testing series products that have been on the market for many years cover cardiovascular and cerebrovascular drug gene testing, mental health, immunology, as well as risk prediction gene testing products for venous thrombosis, Alzheimer's disease, etc., with customers across more than a dozen provinces and cities domestically and an annual sales volume exceeding 600,000 loci. 

Office Address: Building 20, No. 50 Huatuo Road, Daxing Biopharmaceutical Industry Base, Zhongguancun Science Park, Daxing District, Beijing 

Contact Number: 010-82689008